Published in FEBS Lett on April 24, 2002
Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J Biol Chem (2011) 1.96
Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein. Curr Protein Pept Sci (2009) 1.66
Guiding protein aggregation with macromolecular crowding. Biochemistry (2008) 1.23
Elevated levels of brain-pathologies associated with neurodegenerative diseases in the methionine sulfoxide reductase A knockout mouse. Exp Brain Res (2007) 1.21
Methionine sulfoxide reductase A protects dopaminergic cells from Parkinson's disease-related insults. Free Radic Biol Med (2008) 1.13
Methionine oxidation in human IgG2 Fc decreases binding affinities to protein A and FcRn. Protein Sci (2009) 1.12
Polycation-induced oligomerization and accelerated fibrillation of human alpha-synuclein in vitro. Protein Sci (2003) 1.09
Methionine oxidation induces amyloid fibril formation by full-length apolipoprotein A-I. Proc Natl Acad Sci U S A (2010) 1.09
Amyloidogenesis of natively unfolded proteins. Curr Alzheimer Res (2008) 1.08
Structural and morphological characterization of aggregated species of α-synuclein induced by docosahexaenoic acid. J Biol Chem (2011) 1.02
Conditionally and transiently disordered proteins: awakening cryptic disorder to regulate protein function. Chem Rev (2014) 1.00
Alpha-synuclein function and dysfunction on cellular membranes. Exp Neurobiol (2014) 0.99
Smoking and Parkinson's disease: does nicotine affect alpha-synuclein fibrillation? Biochim Biophys Acta (2008) 0.94
Age-related oxidative modifications of transthyretin modulate its amyloidogenicity. Biochemistry (2013) 0.92
Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive element. Int J Mol Sci (2009) 0.92
The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease. Antioxid Redox Signal (2009) 0.90
Methionine oxidation stabilizes non-toxic oligomers of alpha-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions. Biochim Biophys Acta (2009) 0.90
Amylin uncovered: a review on the polypeptide responsible for type II diabetes. Biomed Res Int (2013) 0.89
At low concentrations, 3,4-dihydroxyphenylacetic acid (DOPAC) binds non-covalently to alpha-synuclein and prevents its fibrillation. J Mol Biol (2009) 0.88
Decreased Phosphorylation and Increased Methionine Oxidation of α-Synuclein in the Methionine Sulfoxide Reductase A Knockout Mouse. J Amino Acids (2011) 0.82
Mechanisms of alpha-synuclein action on neurotransmission: cell-autonomous and non-cell autonomous role. Biomolecules (2015) 0.81
Exploring the accessible conformations of N-terminal acetylated α-synuclein. FEBS Lett (2013) 0.79
Thioredoxin system regulation in the central nervous system: experimental models and clinical evidence. Oxid Med Cell Longev (2014) 0.78
Alpha-Synuclein Oligomers-Neurotoxic Molecules in Parkinson's Disease and Other Lewy Body Disorders. Front Neurosci (2016) 0.78
Interactions between calcium and alpha-synuclein in neurodegeneration. Biomolecules (2014) 0.78
Function and dysfunction of α-synuclein: probing conformational changes and aggregation by single molecule fluorescence. Mol Neurobiol (2012) 0.77
Oxidation enhances human serum albumin thermal stability and changes the routes of amyloid fibril formation. PLoS One (2014) 0.77
Effects of Trehalose on Thermodynamic Properties of Alpha-synuclein Revealed through Synchrotron Radiation Circular Dichroism. Biomolecules (2015) 0.76
Role of N-terminal methionine residues in the redox activity of copper bound to alpha-synuclein. J Biol Inorg Chem (2016) 0.75
Formation of covalent di-tyrosine dimers in recombinant α-synuclein. Intrinsically Disord Proteins (2015) 0.75
α-Synuclein structural features inhibit harmful polyunsaturated fatty acid oxidation, suggesting roles in neuroprotection. J Biol Chem (2017) 0.75
Conformational constraints for amyloid fibrillation: the importance of being unfolded. Biochim Biophys Acta (2004) 3.69
Disorder in the nuclear pore complex: the FG repeat regions of nucleoporins are natively unfolded. Proc Natl Acad Sci U S A (2003) 3.07
Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins. J Biol Chem (2002) 2.07
The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils. J Biol Chem (2004) 2.02
The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem (2001) 1.99
The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation. J Biol Chem (2003) 1.97
A general model for amyloid fibril assembly based on morphological studies using atomic force microscopy. Biophys J (2003) 1.93
Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils. Chem Biol (2004) 1.91
The oxidation state of DJ-1 regulates its chaperone activity toward alpha-synuclein. J Mol Biol (2005) 1.74
Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro. Biochemistry (2002) 1.71
Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-beta structure. Proc Natl Acad Sci U S A (2003) 1.67
Lipid binding inhibits alpha-synuclein fibril formation. J Biol Chem (2003) 1.64
Accelerated alpha-synuclein fibrillation in crowded milieu. FEBS Lett (2002) 1.64
Familial Alzheimer's disease mutations alter the stability of the amyloid beta-protein monomer folding nucleus. Proc Natl Acad Sci U S A (2007) 1.55
Conformational behavior and aggregation of alpha-synuclein in organic solvents: modeling the effects of membranes. Biochemistry (2003) 1.51
The effect of macromolecular crowding on protein aggregation and amyloid fibril formation. J Mol Recognit (2004) 1.48
Surface-catalyzed amyloid fibril formation. J Biol Chem (2002) 1.43
GM1 specifically interacts with alpha-synuclein and inhibits fibrillation. Biochemistry (2007) 1.40
Partially folded intermediates in insulin fibrillation. Biochemistry (2003) 1.38
Role of protein-water interactions and electrostatics in alpha-synuclein fibril formation. Biochemistry (2004) 1.35
Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry (2003) 1.33
Early events in the fibrillation of monomeric insulin. J Biol Chem (2005) 1.28
Synergistic effects of pesticides and metals on the fibrillation of alpha-synuclein: implications for Parkinson's disease. Neurotoxicology (2002) 1.25
Structural characterization of the partially folded intermediates of an immunoglobulin light chain leading to amyloid fibrillation and amorphous aggregation. Biochemistry (2007) 1.24
Characterization of oligomeric intermediates in alpha-synuclein fibrillation: FRET studies of Y125W/Y133F/Y136F alpha-synuclein. J Mol Biol (2005) 1.24
Guiding protein aggregation with macromolecular crowding. Biochemistry (2008) 1.23
Structural characteristics of alpha-synuclein oligomers stabilized by the flavonoid baicalein. J Mol Biol (2008) 1.23
Characterization of oligomers during alpha-synuclein aggregation using intrinsic tryptophan fluorescence. Biochemistry (2006) 1.21
Forcing nonamyloidogenic beta-synuclein to fibrillate. Biochemistry (2005) 1.19
The Saccharomyces cerevisiae nucleoporin Nup2p is a natively unfolded protein. J Biol Chem (2002) 1.19
Conformational behavior of human alpha-synuclein is modulated by familial Parkinson's disease point mutations A30P and A53T. Neurotoxicology (2002) 1.19
Methionine oxidation, alpha-synuclein and Parkinson's disease. Biochim Biophys Acta (2004) 1.19
Effect of association state and conformational stability on the kinetics of immunoglobulin light chain amyloid fibril formation at physiological pH. J Biol Chem (2002) 1.18
Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers. FEBS Lett (2003) 1.15
Fluorescence as a method to reveal structures and membrane-interactions of amyloidogenic proteins. Biochim Biophys Acta (2007) 1.15
Mechanistic studies with potent and selective inducible nitric-oxide synthase dimerization inhibitors. J Biol Chem (2001) 1.14
Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease. FASEB J (2004) 1.13
Structural transformations of oligomeric intermediates in the fibrillation of the immunoglobulin light chain LEN. Biochemistry (2003) 1.10
Polycation-induced oligomerization and accelerated fibrillation of human alpha-synuclein in vitro. Protein Sci (2003) 1.09
Effects of nitration on the structure and aggregation of alpha-synuclein. Brain Res Mol Brain Res (2005) 1.09
Annular oligomeric amyloid intermediates observed by in situ atomic force microscopy. J Biol Chem (2004) 1.07
Conformational prerequisites for alpha-lactalbumin fibrillation. Biochemistry (2002) 1.07
Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation. J Biol Chem (2006) 1.06
Role of different regions of alpha-synuclein in the assembly of fibrils. Biochemistry (2007) 1.03
Amino acid determinants of alpha-synuclein aggregation: putting together pieces of the puzzle. FEBS Lett (2002) 1.03
Unraveling multistate unfolding of rabbit muscle creatine kinase. Biochim Biophys Acta (2002) 1.03
Certain metals trigger fibrillation of methionine-oxidized alpha-synuclein. J Biol Chem (2003) 1.03
Elucidation of the molecular mechanism during the early events in immunoglobulin light chain amyloid fibrillation. Evidence for an off-pathway oligomer at acidic pH. J Biol Chem (2002) 1.03
Effect of zinc and temperature on the conformation of the gamma subunit of retinal phosphodiesterase: a natively unfolded protein. J Proteome Res (2003) 1.02
Impact of Tyr to Ala mutations on alpha-synuclein fibrillation and structural properties. Biochim Biophys Acta (2008) 1.02
Stimulation of insulin fibrillation by urea-induced intermediates. J Biol Chem (2004) 1.00
Structure and proposed mechanism for the pH-sensing Helicobacter pylori chemoreceptor TlpB. Structure (2012) 1.00
Molecular mechanisms underlying the flavonoid-induced inhibition of alpha-synuclein fibrillation. Biochemistry (2009) 1.00
Distinct β-sheet structure in protein aggregates determined by ATR-FTIR spectroscopy. Biochemistry (2013) 0.99
Independent heterologous fibrillation of insulin and its B-chain peptide. Biochemistry (2005) 0.96
The chicken-egg scenario of protein folding revisited. FEBS Lett (2002) 0.95
Structural impact of three Parkinsonism-associated missense mutations on human DJ-1. Biochemistry (2008) 0.94
Fibrillation of human insulin A and B chains. Biochemistry (2006) 0.94
Smoking and Parkinson's disease: does nicotine affect alpha-synuclein fibrillation? Biochim Biophys Acta (2008) 0.94
Conformational prerequisites for formation of amyloid fibrils from histones. J Mol Biol (2004) 0.94
Prediction of the association state of insulin using spectral parameters. J Pharm Sci (2003) 0.92
Alpha-synuclein can function as an antioxidant preventing oxidation of unsaturated lipid in vesicles. Biochemistry (2006) 0.92
Methionine oxidation stabilizes non-toxic oligomers of alpha-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions. Biochim Biophys Acta (2009) 0.90
The effect of membranes on the in vitro fibrillation of an amyloidogenic light-chain variable-domain SMA. J Mol Biol (2008) 0.90
Conserved C-terminal charge exerts a profound influence on the aggregation rate of α-synuclein. J Mol Biol (2011) 0.89
At low concentrations, 3,4-dihydroxyphenylacetic acid (DOPAC) binds non-covalently to alpha-synuclein and prevents its fibrillation. J Mol Biol (2009) 0.88
Role of individual methionines in the fibrillation of methionine-oxidized alpha-synuclein. Biochemistry (2004) 0.87
Effect of methionine oxidation on the structural properties, conformational stability, and aggregation of immunoglobulin light chain LEN. Biochemistry (2008) 0.86
Effects of Various Flavonoids on the α-Synuclein Fibrillation Process. Parkinsons Dis (2010) 0.86
Peculiarities of copper binding to alpha-synuclein. J Biomol Struct Dyn (2012) 0.83
Agrin binds alpha-synuclein and modulates alpha-synuclein fibrillation. Glycobiology (2005) 0.83
A model for amyloid fibril formation in immunoglobulin light chains based on comparison of amyloidogenic and benign proteins and specific antibody binding. Amyloid (2003) 0.82
Characterization of the non-fibrillar α-synuclein oligomers. Protein Pept Lett (2011) 0.82
Oxidized quercetin inhibits α-synuclein fibrillization. Biochim Biophys Acta (2013) 0.80
Agrochemicals, α-synuclein, and Parkinson's disease. Mol Neurobiol (2012) 0.80
Structural and functional properties of Yersinia pestis Caf1 capsular antigen and their possible role in fulminant development of primary pneumonic plague. J Proteome Res (2003) 0.78
Concerted action of metals and macromolecular crowding on the fibrillation of alpha-synuclein. Protein Pept Lett (2008) 0.78
Conversion of human alpha-lactalbumin to an apo-like state in the complexes with basic poly-amino acids: toward understanding of the molecular mechanism of antitumor action of HAMLET. J Proteome Res (2005) 0.77